null_results_in_brief

no_association_between_sod2_or_nqo1_genotypes_and_risk_of_bladder_cancer

Paul D. Terry,1,4 David M. Umbach,2 and Jack A. Taylor1,3

1Epidemiology Branch, 2Biostatistics Branch, and 3Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, Department of Health and Human Services, Research Triangle Park, North Carolina; and 4Department of Epidemiology, Emory University School of Public Health, Atlanta, Georgia

Introduction

SOD2 encodes manganese superoxide dismutase, a mitochondrial enzyme that protects the cell against damage from superoxide free radicals. A common polymorphism, a T → C transition (Val16Ala), was shown to alter the manganese superoxide dismutase mitochondrial targeting sequence (1). Animal studies have linked reduction in manganese superoxide dismutase activity to increased DNA damage and higher incidence of cancer (2). NQO1 encodes NAD(P)H dehydrogenase (quinone), a flavoprotein that also protects the cell against cytotoxicity, by promoting the two-electron reduction of quinoid compounds to hydroquinones (3). A common polymorphism, a C → T transition (Pro187Ser), produces significant reductions in enzyme activity in human colon cancer cells (3). Therefore, in the case-control study reported here, we examined the associations between polymorphisms in SOD2 and NQO1, cigarette smoking, and bladder cancer risk.

Materials and Methods

Bladder cancer patients (n = 239) and control individuals (n = 215) were enrolled from the Urology Clinics at Duke University Medical Center and the University of North Carolina Hospitals as previously described (4). Briefly, cases were urology clinic patients with histologically confirmed transitional cell carcinoma. Controls were urology clinic patients without a history of cancer, frequency matched to cases based on ethnicity, sex, and age (10-year intervals). The most common diagnoses among controls were benign prostatic hypertrophy and impotence. Case patients and control subjects were interviewed by trained nurse-interviewers using a structured questionnaire that detailed their smoking, occupational, and other exposure histories.

DNA was extracted from peripheral blood lymphocytes by standard methods and frozen until used. Genotype at each of the two polymorphic sites was determined using allele-specific primer extension reactions followed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Individuals homozygous for the minor allele, heterozygous, or homozygous for the common allele could always be clearly distinguished, with peaks correctly corresponding to predicted masses. Eight subjects were missing genotype data for either SOD2 or NQO1: three cases and one control, all smokers, were missing SOD2; two cases and one control, both smokers, plus one case nonsmoker, were missing NQO1. Thus, 236 cases and 214 control subjects were available for analysis of SOD2 and NQO1, respectively. Information on smoking status was not available for one individual, a case. Unconditional logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (95% CI). Multivariable models included the variables listed in Table 1 legend. Tests for interaction were based on likelihood ratio tests that compared models with and without product terms representing the variables of interest. All statistical tests were two sided.

Results

Participants were mostly males (77% of cases and 81% of controls) and White (91% of cases and 93% of controls). The mean age was 65.7 years (SD = 10.7 years) for cases and 63.3 years (SD = 10.3 years) for controls. We detected no deviations from Hardy-Weinberg equilibrium among cases or controls (P > 0.51 for each locus). The frequency of the variant allele in the entire sample was 50.2% for SOD2 and 17.6% for NQO1.

SOD2 genotype was not associated with bladder cancer risk (Table 1), although the data showed evidence of a small increase in risk among individuals with Ala/Ala or Val/Ala genotypes compared with those with Val/Val. Among smokers, individuals with the Val/Ala genotype showed some indication of increased risk (OR, 1.7; 95% CI, 1.0-2.9), but an elevated OR was not observed for those with the Ala/Ala genotype, thus showing no trend with increasing number of putative risk alleles. NQO1 genotype was not associated with bladder cancer risk (Table 1), although risk estimates for the variant genotype Ser/Ser were unstable due to small numbers. When the association was examined by strata of smoking, a statistically insignificant positive elevated OR was observed among nonsmokers with the presumptive high-risk allele. The latter finding was based on relatively small numbers of cases and controls. For NQO1, the statistical power of a two-tailed level 5 Fisher’s Exact test using the entire sample (239 cases, 215 controls) to detect an OR of 2.0 for carriers of the variant allele compared with those homozygous for the common allele is 94%; using smokers alone (196 cases, 135 controls), power is 83%. For SOD2, the corresponding power values are 80% for the entire sample and 65% for smokers alone (minimal OR detectable with 80% power using smokers alone is ~ 2.3). The results of our study were not altered appreciably by exclusion of the 95 females or 37 non-Whites from the analyses.
Few studies have examined polymorphisms in these metabolism genes with respect to bladder cancer risk (5-9), and they have shown inconsistent findings. Animal experiments and in vitro studies suggest that proteins encoded by SOD2 and NQO1 can modulate DNA damage from reactive oxygen species and, hence, cancer risk (1, 2). We found no association with SOD2 or NQO1 genotype and bladder cancer risk, although the possibility of small increases in risk among individuals with the putative risk alleles cannot be excluded because of the small number of participants in some of the genotype categories.

References


Table 1. Multivariate-adjusted ORs for NQO1 and SOD2 polymorphism genotypes and bladder cancer risk

<table>
<thead>
<tr>
<th>SOD2</th>
<th>Total population</th>
<th>Never smokers</th>
<th>Smokers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cases/controls</td>
<td>OR (95% CI)</td>
<td>Cases/controls</td>
</tr>
<tr>
<td>Val/Val</td>
<td>54/57</td>
<td>1.0 (reference)</td>
<td>10/18</td>
</tr>
<tr>
<td>Val/Ala</td>
<td>122/103</td>
<td>1.4 (0.8-2.2)</td>
<td>18/42</td>
</tr>
<tr>
<td>Ala/Ala</td>
<td>59/54</td>
<td>1.4 (0.8-2.6)</td>
<td>12/19</td>
</tr>
<tr>
<td>Val/Ala or Ala/Ala</td>
<td>181/157</td>
<td>1.4 (0.9-2.3)</td>
<td>30/61</td>
</tr>
<tr>
<td>NQO1 Pro/Pro</td>
<td>156/150</td>
<td>1.0 (reference)</td>
<td>23/59</td>
</tr>
<tr>
<td>Pro/Ser</td>
<td>70/58</td>
<td>1.1 (0.7-1.7)</td>
<td>13/19</td>
</tr>
<tr>
<td>Ser/Ser</td>
<td>9/6</td>
<td>1.4 (0.5-4.4)</td>
<td>3/1</td>
</tr>
<tr>
<td>Pro/Ser or Ser/Ser</td>
<td>79/64</td>
<td>1.1 (0.7-1.7)</td>
<td>16/20</td>
</tr>
</tbody>
</table>

NOTE: Multivariate models included age (continuous variable), sex (female, male), race (White, other), and smoking (duration in 10-year categories, when possible).
No Association Between $SOD2$ or $NQO1$ Genotypes and Risk of Bladder Cancer

Paul D. Terry, David M. Umbach and Jack A. Taylor


Updated version
Access the most recent version of this article at:
http://cebp.aacrjournals.org/content/14/3/753

Cited articles
This article cites 8 articles, 2 of which you can access for free at:
http://cebp.aacrjournals.org/content/14/3/753.full#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://cebp.aacrjournals.org/content/14/3/753.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.